DAM
VYNE icon

Deltec Asset Management’s VYNE Therapeutics VYNE Stock Holding History

Deltec Asset Management’s Portfolio VYNE Stock Details VYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,667
Closed -$4.5K – 184
2022
Q4 		$4.5K Hold
1,667
– – ﹤0.01% 164
2022
Q3 		$7K Hold
1,667
– – ﹤0.01% 224
2022
Q2 		$12K Hold
1,667
– – ﹤0.01% 234
2022
Q1 		$20K Hold
1,667
– – ﹤0.01% 257
2021
Q4 		$31K Hold
1,667
– – 0.01% 254
2021
Q3 		$42K Sell
1,667
-19,805
-92% -$768K 0.01% 273
2021
Q2 		$1.36M Sell
21,472
-3,055
-12% -$242K 0.19% 85
2021
Q1 		$3.02M Sell
24,527
-4,576
-16% -$664K 0.45% 50
2020
Q4 		$3.31M Buy
+29,103
New +$3.66M 0.51% 50

Other funds holding VYNE

DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SCA
STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.36B AUM 23.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Deltec Asset Management's VYNE Position: Q1 2023 in Review

Deltec Asset Management sold out of VYNE Therapeutics (VYNE) in Q1 2023, closing a stake of 1,667 shares — an estimated $4.5K sold.

Deltec Asset Management first reported a position in VYNE in Q4 2020 and held it in 9 quarters. The position peaked at $3.31M in Q4 2020. 23 funds tracked by Wall St. Rank hold VYNE as of Q1 2023.

  • Deltec Asset Management reported no remaining VYNE Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Deltec Asset Management sold 1,667 VYNE Therapeutics shares in Q1 2023, an estimated $4.5K.
  • Deltec Asset Management first reported a position in VYNE Therapeutics in Q4 2020 and held it in 9 quarters.
  • Deltec Asset Management's VYNE Therapeutics position peaked at $3.31M in Q4 2020.
  • 23 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q1 2023.

Based on Deltec Asset Management's 13F filing for Q1 2023, filed 17 Apr 2023.